NASDAQ:GWPH - GW Pharmaceuticals Stock Price, Price Target & More

$132.43 -1.66 (-1.24 %)
(As of 04/22/2018 02:17 AM ET)
Previous Close$132.43
Today's Range$127.8001 - $136.25
52-Week Range$92.65 - $143.37
Volume701,787 shs
Average Volume413,786 shs
Market Capitalization$3.72 billion
P/E Ratio-19.05
Dividend YieldN/A
Beta2.62

About GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals logoGW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Debt-to-Equity Ratio0.01%
Current Ratio11.44%
Quick Ratio11.34%

Price-To-Earnings

Trailing P/E Ratio-19.05
Forward P/E Ratio-13.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales334.33
Cash FlowN/A
Price / CashN/A
Book Value$13.92 per share
Price / Book9.51

Profitability

EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,357.98%
Return on Equity-46.94%
Return on Assets-41.00%

Miscellaneous

Employees583
Outstanding Shares27,770,000

How to Become a New Pot Stock Millionaire

GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals (NASDAQ:GWPH) issued its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.03) by $0.40. The biopharmaceutical company earned $7.73 million during the quarter, compared to analyst estimates of $2.18 million. GW Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. View GW Pharmaceuticals' Earnings History.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for GW Pharmaceuticals.

What price target have analysts set for GWPH?

7 brokerages have issued 1-year price targets for GW Pharmaceuticals' stock. Their predictions range from $61.00 to $205.00. On average, they expect GW Pharmaceuticals' share price to reach $152.1429 in the next year. View Analyst Ratings for GW Pharmaceuticals.

What are Wall Street analysts saying about GW Pharmaceuticals stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (3/21/2018)
  • 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)

Who are some of GW Pharmaceuticals' key competitors?

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
  • Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)

Has GW Pharmaceuticals been receiving favorable news coverage?

Headlines about GWPH stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals earned a news impact score of 0.19 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of GW Pharmaceuticals?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $132.43.

How big of a company is GW Pharmaceuticals?

GW Pharmaceuticals has a market capitalization of $3.72 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals employs 583 workers across the globe.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals (GWPH)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GW Pharmaceuticals (NASDAQ:GWPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for GW Pharmaceuticals in the last 12 months. Their average twelve-month price target is $152.1429, suggesting that the stock has a possible upside of 14.89%. The high price target for GWPH is $205.00 and the low price target for GWPH is $61.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.882.71
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $152.1429$150.2857$152.50$144.5714
Price Target Upside: 14.89% upside13.57% upside23.00% upside26.18% upside

GW Pharmaceuticals (NASDAQ:GWPH) Consensus Price Target History

Price Target History for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018Cantor FitzgeraldBoost Price TargetOverweight -> Overweight$192.00 -> $205.00HighView Rating Details
2/6/2018Bank of AmericaLower Price TargetBuy -> Buy$154.00 -> $149.00HighView Rating Details
2/6/2018Leerink SwannBoost Price TargetOutperform -> Outperform$153.00 -> $157.00HighView Rating Details
12/14/2017Goldman SachsUpgradeNeutral -> Buy$174.00MediumView Rating Details
10/2/2017CowenReiterated RatingOutperform$165.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$154.00MediumView Rating Details
8/8/2017Maxim GroupDowngradeBuy -> Hold$61.00HighView Rating Details
2/7/2017Piper JaffraySet Price TargetBuy$147.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis SecuritiesUpgradeSell -> HoldN/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

GW Pharmaceuticals (NASDAQ:GWPH) Earnings History and Estimates Chart

Earnings by Quarter for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) Earnings Estimates

2018 EPS Consensus Estimate: ($3.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.34)($2.34)($2.34)
Q2 20181$2.50$2.50$2.50
Q3 20181($2.00)($2.00)($2.00)
Q4 20181($1.83)($1.83)($1.83)

GW Pharmaceuticals (NASDAQ GWPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
2/5/2018Q1 2018($2.03)($2.43)$2.18 million$7.73 millionViewN/AView Earnings Details
12/4/2017Q4 2017($1.73)($2.18)$2.50 million$2.86 millionViewN/AView Earnings Details
8/7/20176/30/2017($1.73)($2.07)$2.10 million$3.14 millionViewListenView Earnings Details
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
8/9/2016Q3 2016($1.73)($0.73)$3.36 million$3.10 millionViewN/AView Earnings Details
5/5/2016Q2 2016($1.71)($1.10)$6.86 million$3.81 millionViewN/AView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)$11.42 million$11.52 millionViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
6/3/2013Q2 2013($0.26)$11.76 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GW Pharmaceuticals (NASDAQ:GWPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GW Pharmaceuticals (NASDAQ GWPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 82.50%
Insider Trading History for GW Pharmaceuticals (NASDAQ:GWPH)
Institutional Ownership by Quarter for GW Pharmaceuticals (NASDAQ:GWPH)

GW Pharmaceuticals (NASDAQ GWPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

GW Pharmaceuticals (NASDAQ GWPH) News Headlines

Source:
DateHeadline
FDA Committee Approval Sparks Bullishness On GW PharmaFDA Committee Approval Sparks Bullishness On GW Pharma
seekingalpha.com - April 20 at 5:14 PM
FDA Panel Backs Proposed Epilepsy Drug Derived From CannabisFDA Panel Backs Proposed Epilepsy Drug Derived From Cannabis
www.wsj.com - April 20 at 5:14 PM
An Incredible Signal: 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharmas Epidiolex'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma's Epidiolex
www.msn.com - April 20 at 8:36 AM
20 Marijuana Facts for 4/2020 Marijuana Facts for 4/20
finance.yahoo.com - April 20 at 8:36 AM
FDA Close to Approving First Cannabis-Based DrugFDA Close to Approving First Cannabis-Based Drug
finance.yahoo.com - April 20 at 8:36 AM
GW Pharma wins unanimous recommendation from FDA advisory committee for cannabis-derived drugGW Pharma wins unanimous recommendation from FDA advisory committee for cannabis-derived drug
www.marketwatch.com - April 19 at 5:31 PM
Why This Kids Epilepsy Drug Is Almost Certainly About to Become the 1st FDA Approved Marijuana TreatmentWhy This Kids' Epilepsy Drug Is Almost Certainly About to Become the 1st FDA Approved Marijuana Treatment
fortune.com - April 19 at 5:31 PM
FDA advisory committee backs GW Pharmas cannabidiol for rare forms for epilepsyFDA advisory committee backs GW Pharma's cannabidiol for rare forms for epilepsy
seekingalpha.com - April 19 at 5:31 PM
GW Pharmaceuticals (GWPH) Price Target Increased to $205.00 by Analysts at Cantor FitzgeraldGW Pharmaceuticals (GWPH) Price Target Increased to $205.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 1:22 PM
GW Pharma shares halted pending newsGW Pharma shares halted pending news
seekingalpha.com - April 19 at 8:26 AM
GW Pharmaceuticals Obtains Favorable Confidence From FDA Briefing DocumentsGW Pharmaceuticals Obtains Favorable Confidence From FDA Briefing Documents
seekingalpha.com - April 19 at 8:26 AM
ValuEngine Upgrades GW Pharmaceuticals (GWPH) to BuyValuEngine Upgrades GW Pharmaceuticals (GWPH) to Buy
www.americanbankingnews.com - April 18 at 1:24 PM
GW Pharmaceuticals (GWPH) PT Set at $192.00 by Cantor FitzgeraldGW Pharmaceuticals (GWPH) PT Set at $192.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 18 at 8:37 AM
Epilepsy Drug Made From Marijuana Plant Gets Backing From FDA StaffEpilepsy Drug Made From Marijuana Plant Gets Backing From FDA Staff
fortune.com - April 18 at 8:26 AM
GW Pharma shares surge on FDA briefing document that hints at approval of cannabis-derived drugGW Pharma shares surge on FDA briefing document that hints at approval of cannabis-derived drug
www.marketwatch.com - April 18 at 8:26 AM
GW Pharmaceuticals (GWPH) Is Climbing On FDA NewsGW Pharmaceuticals (GWPH) Is Climbing On FDA News
www.nasdaq.com - April 17 at 5:46 PM
Why This Huge Marijuana Stock Is Soaring 10% TodayWhy This Huge Marijuana Stock Is Soaring 10% Today
finance.yahoo.com - April 17 at 5:46 PM
Outlook positive for GW Pharmas cannabidiol oral solution; shares up 10%Outlook positive for GW Pharma's cannabidiol oral solution; shares up 10%
seekingalpha.com - April 17 at 5:46 PM
Why GW Pharmaceuticals Stock Is Soaring TodayWhy GW Pharmaceuticals Stock Is Soaring Today
investorplace.com - April 17 at 2:09 PM
Investors Are Betting Big Against This Marijuana Stock -- Are They Wrong?Investors Are Betting Big Against This Marijuana Stock -- Are They Wrong?
finance.yahoo.com - April 15 at 9:18 AM
GW Pharmaceuticals (GWPH) Upgraded to "Hold" by BidaskClubGW Pharmaceuticals (GWPH) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM
GW Pharmaceuticals (GWPH) Rating Lowered to Hold at Maxim GroupGW Pharmaceuticals (GWPH) Rating Lowered to Hold at Maxim Group
www.americanbankingnews.com - April 12 at 8:29 PM
GW Pharmaceuticals (GWPH) Given "Outperform" Rating at Leerink SwannGW Pharmaceuticals (GWPH) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - April 11 at 5:35 PM
BidaskClub Downgrades GW Pharmaceuticals (GWPH) to HoldBidaskClub Downgrades GW Pharmaceuticals (GWPH) to Hold
www.americanbankingnews.com - April 10 at 10:00 PM
GW Pharmaceuticals (GWPH) Cut to "Sell" at ValuEngineGW Pharmaceuticals (GWPH) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 12:22 PM
Marijuana Stock Charts: How 3 Pot Plays Performed in Volatile MarketsMarijuana Stock Charts: How 3 Pot Plays Performed in Volatile Markets
finance.yahoo.com - April 7 at 8:39 AM
GW Pharmaceuticals (GWPH) Given Consensus Recommendation of "Hold" by AnalystsGW Pharmaceuticals (GWPH) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 5 at 1:34 AM
Heres Why The Mayo Clinic Owns 10% of This Unknown Epilepsy Stock with Big Upcoming FDA CatalystHere's Why The Mayo Clinic Owns 10% of This Unknown Epilepsy Stock with Big Upcoming FDA Catalyst
finance.yahoo.com - April 4 at 8:31 AM
GW Pharmaceuticals PLC- (GWPH) Upgraded by Zacks Investment Research to "Hold"GW Pharmaceuticals PLC- (GWPH) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 31 at 11:09 AM
BidaskClub Lowers GW Pharmaceuticals PLC- (GWPH) to HoldBidaskClub Lowers GW Pharmaceuticals PLC- (GWPH) to Hold
www.americanbankingnews.com - March 30 at 2:19 PM
GW Pharmaceuticals PLC- (GWPH) Downgraded to Sell at Zacks Investment ResearchGW Pharmaceuticals PLC- (GWPH) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:18 PM
GW Pharmaceuticals PLC- (GWPH) Rating Lowered to Sell at BidaskClubGW Pharmaceuticals PLC- (GWPH) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 29 at 11:29 AM
3 Blockbuster Drug Launches to Watch In 20183 Blockbuster Drug Launches to Watch In 2018
finance.yahoo.com - March 26 at 8:32 AM
GW Pharmaceuticals PLC- (GWPH) Rating Increased to Hold at Zacks Investment ResearchGW Pharmaceuticals PLC- (GWPH) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 25 at 10:49 AM
GW Pharmaceuticals PLC- (GWPH) Upgraded at Zacks Investment ResearchGW Pharmaceuticals PLC- (GWPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 24 at 12:28 AM
Cramer's lightning round: Marijuana stock GW Pharmaceuticals is too hot to buyCramer's lightning round: Marijuana stock GW Pharmaceuticals is too hot to buy
finance.yahoo.com - March 23 at 5:32 PM
Why Didn't Investors Care About This Marijuana Stock's Big News?Why Didn't Investors Care About This Marijuana Stock's Big News?
finance.yahoo.com - March 20 at 8:38 AM
GW Pharmaceuticals PLC- (GWPH) Upgraded to "Hold" at BidaskClubGW Pharmaceuticals PLC- (GWPH) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM
Is This the Next "Big Thing" in Marijuana?Is This the Next "Big Thing" in Marijuana?
finance.yahoo.com - March 17 at 8:39 AM
Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 16 at 8:30 AM
GW Pharma (GWPH) Confirms Notices of Allowance for Five New ... - StreetInsider.comGW Pharma (GWPH) Confirms Notices of Allowance for Five New ... - StreetInsider.com
www.streetinsider.com - March 14 at 8:49 AM
GW Pharma (GWPH) Confirms Notices of Allowance for Five New Epidiolex Patent ApplicationsGW Pharma (GWPH) Confirms Notices of Allowance for Five New Epidiolex Patent Applications
www.streetinsider.com - March 13 at 7:09 PM
Why GW Pharmaceuticals Stock Lost 17.7% in FebruaryWhy GW Pharmaceuticals Stock Lost 17.7% in February
finance.yahoo.com - March 13 at 7:09 PM
Is There a Link Between Marijuana Use and Kidney Disease? The Shocking AnswerIs There a Link Between Marijuana Use and Kidney Disease? The Shocking Answer
finance.yahoo.com - March 12 at 10:26 AM
GW Pharmaceuticals PLC- (GWPH) Given Average Rating of "Hold" by BrokeragesGW Pharmaceuticals PLC- (GWPH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 11 at 1:54 AM
Stock Traders Buy High Volume of GW Pharmaceuticals PLC- Call Options (GWPH)Stock Traders Buy High Volume of GW Pharmaceuticals PLC- Call Options (GWPH)
www.americanbankingnews.com - March 8 at 8:14 AM
GW Pharmaceuticals PLC- Target of Unusually Large Options Trading (GWPH)GW Pharmaceuticals PLC- Target of Unusually Large Options Trading (GWPH)
www.americanbankingnews.com - March 8 at 8:14 AM
America Is Giving Away the $30 Billion Medical Marijuana IndustryAmerica Is Giving Away the $30 Billion Medical Marijuana Industry
finance.yahoo.com - March 7 at 8:28 AM
MYDA Advisors LLC Purchases Shares of 13,000 GW Pharmaceuticals PLC- (GWPH)MYDA Advisors LLC Purchases Shares of 13,000 GW Pharmaceuticals PLC- (GWPH)
www.americanbankingnews.com - March 6 at 2:46 PM
Prisma Capital Partners LP Acquires New Holdings in GW Pharmaceuticals PLC- (GWPH)Prisma Capital Partners LP Acquires New Holdings in GW Pharmaceuticals PLC- (GWPH)
www.americanbankingnews.com - March 6 at 9:11 AM

SEC Filings

GW Pharmaceuticals (NASDAQ:GWPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GW Pharmaceuticals (NASDAQ:GWPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GW Pharmaceuticals (NASDAQ GWPH) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.